Globeimmune (GBIM) Stock Price, News & Analysis

Company Overview

GlobeImmune, Inc. was a biotechnology company focused on developing therapeutic vaccines and immunotherapies for cancer and infectious diseases. The company’s platform, known as Tarmogens, was designed to stimulate targeted immune responses against disease-associated proteins.

GlobeImmune’s development programs included investigational treatments directed at cancer targets such as mutant RAS proteins and telomerase, as well as programs for chronic infectious diseases including hepatitis C and tuberculosis. Its products were in the research and clinical-development stages and were not established commercial therapies.

Based in Colorado, GlobeImmune conducted its activities primarily through research and clinical-development programs in the United States. Public information about the company’s current operating activities and leadership is limited; GlobeImmune was historically a development-stage biotechnology company whose programs and corporate status changed substantially after it discontinued or reassessed several clinical initiatives.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 8,156 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 5/12/2016
• Today: 10/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:GBIM
• Previous Symbol: NASDAQ:GBIM
• CIK: 1245104
• Web: www.globeimmune.com
• Phone: (720) 667-2300
• Fax: 303-625-2710
• Employees: 3
• Year Founded: 1995

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -285.43